Impax settles US Flomax suit
This article was originally published in Scrip
Executive Summary
Impax Laboratories has reached an agreement with Astellas Pharma and Boehringer Ingelheim to settle pending US patent litigation, relating to a generic version of the benign prostatic hyperplasia (BPH) therapy Flomax (tamsulosin).